Match Document Document Title
9040066 Skin rejuvenation cream  
This invention is based upon the discovery that a mixture of ethyl lactate and isoamyl lactate can be used to improve the penetration of active ingredients in skin care formulations through the...
9040261 Compounds as L-cystine crystallization inhibitors and uses thereof  
A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared...
9040481 Methods for treating steatotic disease  
Methods for treating fatty liver disease, e.g., hepatic steatosis, using peptide fragments of the C-terminal end of glucagon-like peptide-1 (GLP-1), e.g., GLP-1(28-36).
9034832 Solid compositions  
The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid...
9034817 sgp130/Fc dimers for treatment of inflammatory disease  
Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is...
9034831 Pharmaceutical composition for a hepatitis C viral protease inhibitor  
Disclosed is a pharmaceutical composition of a hepatitis C viral protease inhibitor which is suitable for oral administration via a liquid- or semi-solid-filled capsule and methods of using this...
9034824 Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof  
Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such...
9034825 Treatment of myocardial injury with humanin analogs  
Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin...
9029332 Cross-linked peptides and proteins, methods of making same, and uses thereof  
Cross-linked proteins and peptides, and methods of making and uses of such cross-linked proteins and peptides. The cross-linked proteins and peptides have rigid, distance-matching bismethylene...
9029331 Glycopegylated granulocyte colony stimulating factor  
The invention relates to methods of preparing and purifying conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking...
9029320 Formulations and methods for weight loss and body contouring  
Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for...
9029327 Vaccine  
Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula I)(SEQ ID NO: 1)(X1)m(X2)n(X3)oX4X5HPX6, for treating and/or...
9029315 Soluble PD-1 variants, fusion constructs, and uses thereof  
The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are...
9029328 Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands  
The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods...
9023807 Methods and compositions for preventing or treating ophthalmic conditions  
The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa,...
9023806 Peptide capable of altering tubulin polymerization and use thereof for inhibiting cell proliferation  
The invention concerns a peptide derived from intermediate filaments and an intermediate filament fragment capable of altering tubulin polymerization and used for inhibiting cell proliferation,...
9023809 Phenylalanine dipeptide derivatives, compositions and use thereof  
Disclosed are a compound of formula I, stereoisomers, pharmaceutically acceptable salts or hydrates thereof, a pharmaceutical composition comprising the same, a process for preparing the same and...
9023805 Increasing cancer patient survival time by administration of dithio-containing compounds  
The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses...
9023789 Amylin analogs and pharmaceutical compositions thereof  
The invention relates to polypeptides comprising an amino acid sequence which is an analog of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for...
9023258 Spray drying vancomycin  
A method and formulation for preparing spray dried vancomycin. In various embodiment, the formulation includes vancomycin HCl (10-20%) and one or more of the following PEG (0-5%), mannitol (0-5%),...
9023799 Method to reduce loss of cardiac function following ischemia/reperfusion  
A method to treat the chronic stage of heart injury after ischemia or reperfusion by administering Midkine to a subject in need of such treatment is described.
9023798 Cystinosin replacement factor  
The present invention provides compositions and methods for providing factor replacement therapy. In particular, the present invention provides replacement therapy for subjects suffering from...
9023808 Macrocyclic inhibitors of hepatitis C virus  
Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein the dashed line, X, R1, R2, R3, R4, R5, R6, and R7 have defined meanings; the preparation...
9018173 Materials and methods for suppressing inflammatory and neuropathic pain  
N-type voltage-gated calcium channels (CaV2.2) are critical mediators of neurotransmitter release and are thought to be involved with transmission of nociception. The use of conventional CaV2.2...
9018170 Reduced volume formulation of glatiramer acetate and methods of administration  
A method for reducing frequency of relapses in a human patient afflicted with relapsing-remitting multiple sclerosis (RRMS) comprising administering to the patient 0.5 ml of an aqueous...
9018172 Modification of peptides via SNAr reactions of thiols with fluorinated aromatics  
Disclosed are compounds and methods relating to a chemical transformation for the conjugation of unprotected peptide biomolecules via a SNAr process between highly fluorinated aryl moieties and...
9011867 Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (MGUS) or of smoldering multiple myeloma (SMM)  
The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of...
9012409 B7-H5, a costimulatory polypeptide  
B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.
9012408 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis  
The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering...
9012403 Peptides as active agents to stabilize biological barriers  
The present invention relates to compounds, in particular peptides which are capable of stabilizing barrier functions of epithelium and endothelium. The peptides and other compounds of the present...
9011883 Reducing post-operative adhesion formation with intraperitoneal glutamine  
Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.
9012400 Neuregulin peptides and their use  
Neuregulin peptides useful in, for example, methods and compositions comprising preventing, treating or delaying various diseases or disorders are described.
9012407 Therapies which act on neuropeptide S receptors  
Compositions and methods that act on Neuropeptide S receptors (NPSR) (also known as “TGR23” or “vasopressin receptor-related receptor 1 (VRR1)”) to cause desired effects in the bodies of human or...
9011853 B7-H4 fusion proteins and methods of use thereof  
Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide,...
9012401 Growth factor mutants with improved biological activity  
The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity.
9006186 Selective targeting agents for mitochondria  
The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the...
9005616 Methods and compositions for the inhibition of transplant rejection  
Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably...
9006170 Compositions for elastogenesis and connective tissue treatment  
The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and...
9006185 Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases  
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences,...
9006181 Treatment of renal dysfunction and multiple myeloma using PACAP compounds  
The present invention relates to methods and compositions for the treatment, management, or prevention of multiple myeloma and/or renal dysfunction in mammals. The methods of the invention...
9006183 Methods of protecting against apoptosis using lipopeptides  
The use of lipopeptides as inducers of NF-κB for the protection of mammals from the effects of apoptosis is described.
8999925 Arenavirus inhibiting peptides and uses therefor  
The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein...
8999932 Therapeutic agents for reducing parathyroid hormone levels  
Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein...
8999927 Glial cell line-derived neurotrophic factor (GDNF) compositions and use thereof  
Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments,...
8999940 Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal  
There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as...
8999935 Treatment of osteoporosis in peri- and post-menopausal women with hepcidin  
The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves...
8999939 Hair treatment agents having low-dose oligopeptides  
A hair treatment agent having advantageous properties is provided. The hair treatment agent contains, based on weight of the agent, 0.00001 to ≦0.05% by weight of at least one oligopeptide having...
8993523 Dimeric IAP inhibitors  
The present invention provides compounds of formula M-L-M′ (where M and M′ are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be...
8992940 Agent for treating allergic or hypersensitivity condition  
The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated...
8993581 Methods for treating viral disorders  
Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are...